Skin Microbiome Transplantation for Chronic Dermatologic Disorders

Abstract

Skin microbiome transplantation is an emerging therapeutic strategy aimed at restoring microbial equilibrium in chronic dermatologic conditions. This review synthesizes current scientific understanding, clinical evidence, and recent advances, focusing on the mechanisms, clinical applicability, and future potential of microbiome manipulation in disorders such as atopic dermatitis, psoriasis, and chronic wounds. Emphasis is placed on practical implications, patient selection, and integration with existing guidelines to inform clinical decision-making for healthcare professionals.

Introduction

The human skin harbors a diverse and dynamic microbial ecosystem, influencing cutaneous health and disease. Disruption of the skin microbiota—termed dysbiosis—has been implicated in a spectrum of chronic dermatologic disorders, prompting investigation into microbiome modulation as a therapeutic modality. Skin microbiome transplantation (SMT), analogous to fecal microbiota transplantation in gastrointestinal disease, offers a novel, mechanism-based intervention for restoring eubiosis and mitigating disease activity. This review explores the scientific rationale, clinical evidence, and practical considerations for SMT in chronic dermatologic conditions, with a focus on recent PubMed-indexed studies and evolving guidelines.

Epidemiology / Disease Burden

Chronic dermatologic disorders such as atopic dermatitis, psoriasis, hidradenitis suppurativa, and chronic non-healing wounds are prevalent, affecting millions globally. Atopic dermatitis alone impacts up to 20% of children and 3% of adults worldwide. These conditions are associated with significant morbidity, healthcare utilization, and diminished quality of life. Recalcitrant cases frequently exhibit resistance to standard therapies, underscoring the need for innovative approaches. The high burden on healthcare systems and patients alike necessitates exploration of alternative interventions, including microbiome-targeted therapies.

Pathophysiology

The pathogenesis of chronic dermatologic disorders is multifactorial, involving genetic predisposition, immune dysregulation, barrier dysfunction, and environmental factors. A growing body of evidence implicates dysbiosis-characterized by reduced microbial diversity and overrepresentation of pathogenic taxa-in disease progression. In atopic dermatitis, for example, Staphylococcus aureus colonization exacerbates inflammation and barrier impairment. Conversely, beneficial commensals such as Staphylococcus epidermidis and Cutibacterium acnes contribute to immune modulation and pathogen suppression. SMT aims to re-establish a balanced microbiota, thereby restoring homeostasis and attenuating disease activity through competitive exclusion, production of antimicrobial peptides, and modulation of host immune responses.

Risk Factors

Risk factors for dysbiosis-mediated dermatologic disease include genetic mutations affecting skin barrier proteins (e.g., filaggrin), chronic use of topical or systemic antimicrobials, environmental pollutants, and underlying immunologic abnormalities. Additionally, factors such as excessive hygiene, altered pH, and exposure to harsh chemicals disrupt the native microbiota, predisposing individuals to recurrent or chronic skin conditions. Understanding these risk factors aids in identifying candidates who may benefit most from microbiome-based interventions.

Clinical Features

Patients with microbiome-associated dermatologic disorders typically present with chronic, relapsing inflammation, pruritus, erythema, and eczematous or psoriasiform plaques. Secondary infection, persistent colonization, and poor response to standard topical or systemic therapies are common clinical hallmarks. In chronic wounds, delayed healing, malodor, and recurrent infection signal underlying microbial imbalance. Careful assessment of clinical phenotype and disease chronicity is essential for selecting appropriate management strategies, including consideration of SMT.

Diagnosis

Diagnosis relies on clinical examination, supported by microbiological assessment through culture, molecular sequencing (e.g., 16S rRNA), and metagenomic analysis to characterize microbial diversity and identify pathogenic overgrowth. Advanced diagnostic platforms enable precise delineation of dysbiotic profiles, facilitating targeted therapeutic interventions. Biomarkers such as elevated S. aureus abundance or reduced commensal diversity serve as indicators for potential benefit from SMT. Integration of microbiome diagnostics into clinical practice remains an area of active development and research.

Treatment & Management

Standard management includes barrier repair, topical corticosteroids or calcineurin inhibitors, systemic immunomodulators, and targeted biologic therapies. However, recalcitrant cases often exhibit poor response, necessitating adjunctive or alternative strategies. SMT involves topical or, less commonly, procedural application of microbiota harvested from healthy donors or cultivated consortia. Protocols vary with respect to donor screening, processing, and administration, but safety and donor compatibility remain paramount. Early-phase clinical trials have demonstrated reductions in disease severity and pathogenic colonization, particularly in atopic dermatitis, with favorable safety profiles. Adjunctive use alongside conventional therapies may enhance efficacy and reduce reliance on immunosuppression.

Recent Advances / Emerging Therapies

Recent advances include the development of defined microbial consortia, synthetic microbiome formulations, and personalized microbiome therapies tailored to individual dysbiotic signatures. Genetically engineered commensals capable of delivering therapeutic molecules or modulating host immunity represent a frontier in SMT. Innovations in delivery systems, such as encapsulated or hydrogel-based vehicles, enhance retention and colonization efficiency. Ongoing clinical trials are evaluating the efficacy of these approaches in a variety of dermatologic indications, with preliminary data supporting durable clinical improvement and restoration of microbial diversity. Integration of multi-omics analytics facilitates the identification of therapeutic targets and predictive biomarkers, guiding personalized treatment regimens.

Guideline Recommendations

While SMT is not yet incorporated into formal consensus guidelines, expert panels and specialty societies acknowledge its potential and recommend consideration in refractory cases within research settings. Rigorous donor screening, standardized protocols, and robust safety monitoring are emphasized. The need for large-scale, randomized controlled trials is widely recognized to validate efficacy, optimize protocols, and establish regulatory frameworks. Interim guidance advocates for multidisciplinary collaboration, informed consent, and long-term follow-up in clinical investigations involving SMT.

Conclusion

Skin microbiome transplantation represents a promising, mechanism-driven adjunct for the management of chronic dermatologic disorders characterized by dysbiosis. Evidence to date supports its safety and potential efficacy, particularly in recalcitrant atopic dermatitis and chronic wounds. Continued research is required to refine patient selection, standardize protocols, and integrate microbiome diagnostics into clinical workflows. As the field evolves, SMT may become a valuable tool in the armamentarium of dermatologic therapeutics, offering hope for improved outcomes in patients with challenging cutaneous disease.